Sir, Local safety of repeated intravitreal Ozurdex
The article entitled 'Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion' 1 highlights the significant cataract progression in eyes receiving more than one Ozurdex implant. We retrospectively reviewed the charts of all patients with macular edema secondary to retinal vein occlusion (RVO) refractory to current therapies and treated with Ozurdex from April 2010 until March 2012.
The mean age of patients with branch RVO (n ¼ 33) was 72.4. In eyes receiving a second Ozurdex implant, four out of the five phakic eyes showed progression of cataract requiring surgery. We registered one case of anterior chamber migration resulting in a bullous keratopathy. 2 The mean age of patients with CRVO (n ¼ 23) was 68.3. In eye receiving a second Ozurdex implant, four out of the six phakic eyes showed progression of cataract requiring surgery.
Real-life studies are necessary in order to better define the safety and efficacy of new therapeutic approaches. Although the GENEVA study 3 reported an incidence of 29.8% of cataract progression in eyes receiving a second Ozurdex intravitreal implant, Mayer et al 1 found a significant higher proportion of these eyes in their study after a third implant (50.0%), and we also evidenced a higher progression of lens opacity in patients with macular edema secondary to RVO refractory to conventional therapies receiving a second implant (75.0% in branch RVO and 66.7% in central RVO). These data should be taken into account when an individualized strategy is planned for patients with RVO.
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The letter 'Local safety of repeated intravitreal Ozurdex' by Hernández-Martinez et al 1 highlights the impact of intravitreal Dexamethason-implant (Ozurdex) on lens opacification. They showed in a retrospective review that four out of five (BRVO) or six (CRVO) eyes receiving a second Ozurdex showed a progression of cataract requiring surgery. As the Geneva study has shown, 2 Ozurdex is an effective treatment option for macular edema due to RVO. While our study 3 confirms these data, it furthermore shows a significant progression in cataract formation after the third intravitreal injection. Therefore, it is mandatory to consider along with age and intraocular pressure the lens status when using intravitreal Ozurdex. In the mentioned retrospective case series by Hernández-Martinez et al, it is not clear whether there is a progression of an existing cataract to a cataract requiring surgery or clear lenses showing a beginning of cataract formation. Furthermore, no objective classification of lens opacification was assessed to show which kind of lens opacification shows a significant progression requiring surgery. It is also necessary to investigate recurrence rates, treatment intervals and the data should be supplemented by a clear follow-up time. We agree that long-term follow-up data are needed to confirm present observations. As the adequate treatment of macular edema due to RVO is still a challenge, treatment possibilities including intravitreal steroids, anti-VEGF substances, laser photocoagulation or combinations are safe and effective options after taking into account the pathogenesis of retinal vein occlusion.
